News & Updates

In cutaneous squamous cell carcinoma patients treated with cemiplimab, prior radiotherapy is associated with improved progression-free survival (PFS). This finding suggests the potential for combination treatment with cemiplimab plus radiotherapy.

In the phase III LMS04 trial, induction therapy with doxorubicin and trabectedin, followed by trabectedin maintenance, improved survival in patients with metastatic or surgically unresectable soft-tissue or uterine leiomyosarcoma (LMS).

Sacubitril/valsartan appears to be safe and beneficial in the treatment of children with heart failure (HF) attributable to systemic left ventricular systolic dysfunction (LVSD), with the drug having comparable efficacy as enalapril, according to the 52-week data from the phase 2/3 PANORAMA-HF* trial.

A pharmacist-managed telemedicine during the COVID-19 pandemic has resulted in improvements in appointment adherence in the hospital-based (HB) clinic and increased reimbursement in the physician-based (PB) clinic, reports a study. Healthcare outcomes, however, show no significant change.

Among patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC), treatment with a sequential chemoradiotherapy (SCRT) regimen is noninferior to the induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) protocol in terms of 3-year failure-free survival (FFS), results of a phase III trial have shown.